BeyondSpring Inc
 | |
| | |
| BeyondSpring Inc | |
|---|---|
| Type | Public |
| Industry | Pharmaceuticals |
| Founded | 2013 |
| Headquarters | New York, NY, United States |
| Key people | Lan Huang (Co-Founder, CEO), Richard A. Brand (CFO), Ramon W. Mohanlal (Chief Medical Officer), Gordon L. Schooley (Chief Regulatory Officer) [1] |
| Number of employees | 20 [2] |
BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. It focuses on the development of innovative immuno-oncology cancer therapies. Its products in pipeline includes Plinabulin, an immuno-oncology agent in Phase 3 clinical trial for the reduction of Docetaxel-induced Neutropenia and another Phase 3 clinical trial as an anticancer agent in combination with Docetaxel in advanced non-small cell lung cancer. [3]
Contents
Products
Plinabulin is an anti-cancer agent with a unique mechanism of action. It is a multi-target agent that has been shown to exhibit anti-tumor activity through anti-angiogenesis, obliteration of existing tumor vasculature and induction of tumor cell apoptosis via the JNK pathway. [4]
Plinabulin has the potential to fill an unmet medical need by improving outcomes as a second line and third line treatment for patients with advanced non-small cell lung cancer (NSCLC) and preventing neutropenia induced by docetaxel. [5]
As a tubulin depolymerizing agent, Plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment:
- Immune enhancing effects via dendritic cell maturation
- Tumor cell apoptosis via activation of RAS-JNK pathway
- Vascular disruptive effects
Given Plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications:
- Immuno-oncology, with immune checkpoint inhibitors in NSCLC
- CNS malignancies including glioblastoma (GBM)
- KRAS positive mutant cancers
Controversies
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| April 14, 2023 | stockresearchhq | BeyondSpring Inc $BYSI quarterly revenue growth rate YoY of 87.80% ranked
⭐⭐⭐⭐⭐ in our db. Impressive! https://t.co/s6HQSVFp3c |
| April 11, 2023 | fundamentalsbot | BeyondSpring Inc's quarterly revenue growth rate YoY of 87.80% ranked 490 out of 5744 companies in our database.… https://t.co/sqKnQ5K6HZ |
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines
- ↑ http://www.beyondspringpharma.com/en/about/management/
- ↑ http://www.nasdaq.com/markets/ipos/company/beyondspring-inc-1008377-82102
- ↑ http://www.bloomberg.com/Research/stocks/private/snapshot.asp?privcapid=318874853
- ↑ http://www.fiercebiotech.com/biotech/beyondspring-pharmaceuticals-names-dr-yan-sun-as-principal-investigator-for-global-phase-3
- ↑ http://www.beyondspringpharma.com/en/plinabulin/
- ↑ https://www.linkedin.com/company/beyondspring-pharmaceuticals
Top Authors
Verification history
2,924 days ago- View all verifications
